Microbial Immunotherapy for Preterm Birth

About Freya Biosciences

Freya Biosciences is pioneering a new class of microbial immunotherapies targeting the immune drivers of reproductive system diseases. The company has built a proprietary data platform integrating multi-omic analyses from clinical trials to identify and develop treatments for conditions such as IVF failure, endometriosis-associated infertility, and preterm birth. Backed by premier investors and led by a team with a strong track record in drug development and microbiome science, Freya is advancing its pipeline through strategic clinical partnerships. Its core hypothesis is that restoring a healthy microbiome can resolve local inflammation and improve reproductive health outcomes.

Therapeutic Areas